HALO
Halozyme Therapeutics, Inc.
stockNASDAQ
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 103.63 | 2026-11-06 | -3.29% | -0.152 |
| 1M | 109.62 | 2026-10-13 | -8.57% | 0.404 |
| 3M | 100.67 | 2026-08-13 | -0.45% | 0.412 |
| 6M | 70.03 | 2026-05-13 | +43.11% | 0.371 |
| 1Y | 71.19 | 2025-11-13 | +40.78% | 0.577 |
| 2Y | 58.61 | 2024-11-13 | +71.00% | — |
| 5Y | 38.96 | 2021-11-12 | +157.24% | 0.731 |
Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock price today is $100.22, and today's volume is 1,945,246. HALO is down 0.447% today. The 30 day average volume is 2.32M. HALO market cap is $11.43B with 114.01M shares outstanding.